Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b studyJeffrey S. Weber, Tal Zaks, Adnan Khattak et al.|The Lancet|2024Cited by 729
Clinicopathological and Molecular Characteristics of Pleomorphic Invasive Lobular CarcinomaJennifer Segar, Pavani Chalasani|International Journal of Breast Cancer|2020Cited by 7